Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 204.49B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 12.61 |
| Forward PE | 10.54 |
| Dividend | 2.91 (3.52%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 541 |
| Average Volume | 4,264 |
| Open | 82.40 |
| Previous Close | 82.70 |
| Day's Range | 82.30 - 83.00 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 74.18 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in ...
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in a...
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Merck (MRK) Gains EU Approval for Subcutaneous Keytruda
Merck (MRK) Gains EU Approval for Subcutaneous Keytruda
Merck gets EU nod for subcutaneous version of Keytruda
Merck's Keytruda wins EU approval for a new injectable form, offering greater treatment options for adults. Read more here.
Merck's (MRK) HIV Treatment Matches Gilead's in Key Trial
Merck's (MRK) HIV Treatment Matches Gilead's in Key Trial
Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial
Merck (MRK) Shares Positive Phase 3 Trial Results for HIV Treatment
Merck (MRK) Shares Positive Phase 3 Trial Results for HIV Treatment
Merck (MRK) Gains EU Approval for New Keytruda Administration
Merck (MRK) Gains EU Approval for New Keytruda Administration
Merck's oral HIV treatment meets main goal in late-stage study
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the...
European Commission Approves Subcutaneous Administration of KEYTRUDA (pembrolizumab) for All Adult Indications Approved in the European Union
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administrat...
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous ...
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (C...
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (Cp...
Daily Dividend Report: MRK,PWR,MOS,GIS,PEG
Merck, known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the firs...
Merck (MRK) Increases Quarterly Dividend by 4.9%
Merck (MRK) Increases Quarterly Dividend by 4.9%
Merck (MRK) Increases Quarterly Dividend for 2026
Merck (MRK) Increases Quarterly Dividend for 2026
Merck raises quarterly dividend by 4.9% to $0.85/share
Merck raises quarterly dividend by 4.9% to $0.85/share, with a 3.54% yield. See payout dates and analysis.
Merck Announces First-Quarter 2026 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2026 Dividend.
Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go
Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.
Merck (MRK) Announces Significant Layoffs in New Jersey
Merck (MRK) Announces Significant Layoffs in New Jersey